Haemonetics Corporation
$5.66B- Market cap
- $4.66B
- Debt
- +$1.24B
- Cash
- −$245.44M
Capital structure 79% equity / 21% debt · EV / Revenue 4.24x · EV / EBITDA 21.48x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: HAE stock price at premium vs BCC $102.34 current versus $45.08 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BCC's multiple
Implied fair value · at HAE's multiple
Snapshot Sep 8, 11:12 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · BCC FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.24x · EV / EBITDA 21.48x
Capital structure 86% equity / 14% debt · EV / Revenue 0.42x · EV / EBITDA 12.21x
HAE carries the larger enterprise value at $5.66B against $2.68B; BCC trades on the lower EV / Revenue multiple (0.42x vs 4.24x); BCC on the lower EV / EBITDA (12.21x vs 21.48x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Boise Cascade Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.56x
0.21x
Net debt / EBITDA
Leverage against operating earnings
3.80x
-0.15x
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
$477.22M
Total debt
Interest-bearing obligations outstanding
$1.24B
$445.41M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.